Weight gain
Drug research and approvals for weight gain: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 73 studies of weight gain are recruiting on ClinicalTrials.gov, and Health Canada has authorized 6 drug trials for it since 2013.
- Recruiting worldwide: 73
- Trials authorized in Canada: 6
- FDA orphan approvals: 0
- EU medicines: 0
- Mother and Offspring's Nutritional Status -Pregnancy After Maternal Bariatric SurgeryNCT07877233 · Not reported · Helse Nord-Trøndelag HF · starts Dec 25, 2025
- Effects of Nitraria Retusa Infusion on Clozapine-induced Metabolic Side EffectsNCT07817069 · Not applicable · Faculty of Medicine, Sousse · starts Jan 3, 2026
- Development of a Pregnancy Weight Management Service ModelNCT07814885 · Not applicable · Mackay Medical College · starts Dec 1, 2025
- A Relation Between Craving Induction and Treatment Response in Deep Transcranial Magnetic Stimulation (dTMS) for…NCT07805980 · Not applicable · Second Xiangya Hospital of Central South University · starts Oct 1, 2026
- The Safety and Effectiveness of dTMS for Reducing Antipsychotic-induced Weight GainNCT07795554 · Not applicable · Second Xiangya Hospital of Central South University · starts Nov 1, 2026
- An Online Intuitive Eating Program for Pregnant Women With Obesity to Support Well-BeingNCT07792837 · Not applicable · San Diego State University · starts Nov 1, 2026
- Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving LorlatinibNCT07782359 · Phase 1 · University of Chicago · starts Oct 22, 2026
- Gestational Response, Outcomes, and Weight After GLP-1 UseNCT07743567 · Not reported · University of Kansas Medical Center · starts Apr 13, 2026
- Evaluation of the Nutritional Value of a New Hydrolysed Rice Protein-based FormulaNCT07686224 · Not applicable · Health and Happiness Research Limited · starts Aug 3, 2026
Phase 3 2
- OlanzapineSerotonin 2a (5-HT2a) receptor antagonist
- ZonisamideSodium channel alpha subunit blocker
Phase 2 6
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- OxytocinOxytocin receptor agonist
- Tenofovir alafenamideHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
- DolutegravirHuman immunodeficiency virus type 1 integrase inhibitor
- BetahistineHistamine H3 receptor antagonist
- Miricorilant
Phase 1 or earlier 1
How its trials ended
423 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 90 whose ending is known, 49% met their primary endpoint, 9% missed it and 42% stopped early.
- Completed, result not reported20849%
- Ongoing8119%
- Met its primary endpoint4410%
- Status unknown4410%
- Stopped: other or unclear205%
- Missed its primary endpoint82%
- Stopped: enrollment or feasibility72%
- Stopped: sponsor or business decision41%
- Stopped: lack of efficacy31%
- Stopped: funding31%
- Stopped: safety1<1%
| Mar 28, 2025 | Safely optimizing body weight with mifomelatide (TCMCB07) in patients with newly diagnosed colorectal cancer (CRC) or pancreatic ductal adenocarcinoma (PDAC)…Mifomelatide (TCMCB07) | Endevica Bio | Ongoing |
| Jul 26, 2022 | Metformin for antipsychotic-induced weight gain in adults with intellectual disability: a double-blind randomized control trialMetformin | Centre for Addiction and Mental Health | Ongoing |
| Jan 26, 2021 | A pilot open-label study examining glucagon like peptide-1 receptor agonist(GLP-1RA) for antipsychotic induced weight gain: an algorithmic approachOzempic (semaglutide) / Humalog (insulin lispro) | Centre for Addiction and Mental Health | Closed |
| Feb 17, 2016 | Topiramate in treatment refractory psychotic illness: effects on weight gain and psychopathologyTopiramate | Centre for Addiction and Mental Health | Closed |
| Aug 6, 2013 | Metformin for attenuation of early clozapine-associated weight gain in a first-episode schizophrenia population: a randomized, placebo-controlled studyMetformin | Centre for Addiction and Mental Health | Pending |
| Jul 11, 2013 | A randomized comparison of osmotic release oral system methylphenidate and cognitive behavioural therapy for the treatment of obese patients with binge eating…Methylphenidate | Centre for Addiction and Mental Health | Closed |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA